Neurogene (NGNE) Operating Expenses (2013 - 2026)

Neurogene's Operating Expenses history runs 14 years deep, the most recent figure standing at $33.3 million for Q1 2026.

• Quarterly Operating Expenses rose 28.67% year-over-year to $33.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.8 million (up 22.15% YoY) and the FY2025 annual result came in at $103.3 million, up 23.7% from the prior year.
• Operating Expenses was $33.3 million for Q1 2026 at Neurogene, up from $27.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $33.3 million in Q1 2026 and bottomed at $11.7 million in Q4 2022.
• A 5-year average of $19.5 million and a median of $18.8 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses dropped 23.09% — and 2024, when it jumped 67.19%.
• Neurogene's Operating Expenses stood at $11.7 million in 2022, then rose by 26.24% to $14.7 million in 2023, then surged by 46.01% to $21.5 million in 2024, then increased by 27.97% to $27.5 million in 2025, then rose by 21.14% to $33.3 million in 2026.
• Business Quant data shows NGNE's Operating Expenses at $33.3 million in Q1 2026, $27.5 million in Q4 2025, and $23.8 million in Q3 2025.